Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Randolph Hecht

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 8, 2023
Next-Generation Approaches to Immuno-Oncology in GI CancersJ Randolph Hecht, Jasmine Mitchell, Maria Pia Morelli, et al.
The Oncologist|March 2, 2017
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic <i>KRAS</i> Mutant Colorectal AdenocarcinomaJ Randolph Hecht, Al B Benson, Dmitry Vyushkov, et al.
Cancer|May 10, 2002
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinomaMaria L Delioukina, Diane Prager, Mandy Parson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancerCharles S Fuchs, Melvin R Moore, Graydon Harker, et al.
Cancer|March 29, 2006
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 studyJaffer A Ajani, J Randolph Hecht, Linus Ho, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2007
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCarolyn D Britten, Fairooz Kabbinavar, J Randolph Hecht, et al.
The Oncologist|March 2, 2017
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic AdenocarcinomaAl B Benson, Zev A Wainberg, J Randolph Hecht, et al.
Expert Review of Anticancer Therapy|November 13, 2015
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapyKevin J Harrington, Igor Puzanov, J Randolph Hecht, et al.
Cancer Treatment Reviews|July 30, 2015
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancerJ Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, et al.
Clinical Colorectal Cancer|May 19, 2015
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal CancerJ Randolph Hecht, Allen Cohn, Shaker Dakhil, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 8, 2023
Next-Generation Approaches to Immuno-Oncology in GI CancersJ Randolph Hecht, Jasmine Mitchell, Maria Pia Morelli, et al.
The Oncologist|March 2, 2017
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic <i>KRAS</i> Mutant Colorectal AdenocarcinomaJ Randolph Hecht, Al B Benson, Dmitry Vyushkov, et al.
Cancer|May 10, 2002
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinomaMaria L Delioukina, Diane Prager, Mandy Parson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancerCharles S Fuchs, Melvin R Moore, Graydon Harker, et al.
Cancer|March 29, 2006
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 studyJaffer A Ajani, J Randolph Hecht, Linus Ho, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2007
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCarolyn D Britten, Fairooz Kabbinavar, J Randolph Hecht, et al.
The Oncologist|March 2, 2017
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic AdenocarcinomaAl B Benson, Zev A Wainberg, J Randolph Hecht, et al.
Expert Review of Anticancer Therapy|November 13, 2015
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapyKevin J Harrington, Igor Puzanov, J Randolph Hecht, et al.
Cancer Treatment Reviews|July 30, 2015
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancerJ Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, et al.
Clinical Colorectal Cancer|May 19, 2015
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal CancerJ Randolph Hecht, Allen Cohn, Shaker Dakhil, et al.
Pageof 9